Peihua Lu

2.4k total citations
74 papers, 1.6k citations indexed

About

Peihua Lu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Peihua Lu has authored 74 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 21 papers in Molecular Biology and 14 papers in Hematology. Recurrent topics in Peihua Lu's work include CAR-T cell therapy research (59 papers), Acute Lymphoblastic Leukemia research (13 papers) and Viral Infectious Diseases and Gene Expression in Insects (11 papers). Peihua Lu is often cited by papers focused on CAR-T cell therapy research (59 papers), Acute Lymphoblastic Leukemia research (13 papers) and Viral Infectious Diseases and Gene Expression in Insects (11 papers). Peihua Lu collaborates with scholars based in China, United States and Australia. Peihua Lu's co-authors include Robert S. Negrin, Junfang Yang, Xian Zhang, Jingjing Li, Jianping Zhang, Xin‐an Lu, Xiaosu Zhou, Xiangyu Zhao, Dao‐Pei Lu and Min Xiong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Peihua Lu

71 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peihua Lu China 18 1.2k 553 380 356 275 74 1.6k
Colette Chaney United States 13 1.3k 1.1× 733 1.3× 380 1.0× 432 1.2× 354 1.3× 19 1.7k
Haruko Tashiro Japan 13 1.3k 1.1× 536 1.0× 477 1.3× 449 1.3× 166 0.6× 57 1.6k
Yongxian Hu China 21 1.1k 0.9× 353 0.6× 475 1.3× 324 0.9× 196 0.7× 119 1.4k
Corinne Summers United States 15 1.3k 1.1× 253 0.5× 319 0.8× 411 1.2× 158 0.6× 42 1.5k
Colleen Annesley United States 19 1.5k 1.3× 305 0.6× 445 1.2× 450 1.3× 314 1.1× 52 1.8k
Sarah Tettamanti Italy 15 947 0.8× 536 1.0× 406 1.1× 358 1.0× 266 1.0× 44 1.2k
Rayne H. Rouce United States 17 1.6k 1.3× 924 1.7× 554 1.5× 488 1.4× 206 0.7× 54 2.0k
Gerrit Weber United States 19 993 0.8× 677 1.2× 437 1.1× 285 0.8× 245 0.9× 28 1.5k
Maksim Mamonkin United States 19 1.8k 1.5× 746 1.3× 738 1.9× 691 1.9× 185 0.7× 59 2.1k
Monica Casucci Italy 16 1.6k 1.3× 654 1.2× 527 1.4× 466 1.3× 217 0.8× 35 1.9k

Countries citing papers authored by Peihua Lu

Since Specialization
Citations

This map shows the geographic impact of Peihua Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peihua Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peihua Lu more than expected).

Fields of papers citing papers by Peihua Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peihua Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peihua Lu. The network helps show where Peihua Lu may publish in the future.

Co-authorship network of co-authors of Peihua Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Peihua Lu. A scholar is included among the top collaborators of Peihua Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peihua Lu. Peihua Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Tong, Yang Zhang, Fang Wang, et al.. (2023). Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation. Leukemia & lymphoma. 64(13). 2133–2139.
3.
Wu, Xian, Dong Wang, Jing Wang, et al.. (2023). 289MO Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study. Annals of Oncology. 34. S1587–S1587. 1 indexed citations
4.
Zhang, Xian, Junfang Yang, Jingjing Li, et al.. (2023). Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7‐targeted chimeric antigen receptor‐T cell therapy. American Journal of Hematology. 98(12). 1898–1908. 24 indexed citations
5.
6.
Cao, Xingyu, Jianping Zhang, Yanli Zhao, et al.. (2023). Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant. Frontiers in Immunology. 14. 1191382–1191382. 7 indexed citations
7.
Li, Jingjing, Junfang Yang, Xian Zhang, et al.. (2022). Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Cells. 11(24). 4085–4085. 8 indexed citations
8.
Nannya, Yasuhito, Auro Viswabandya, & Peihua Lu. (2022). Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia. PubMed. 5(4). S25–S33. 2 indexed citations
9.
Hu, Yongxian, Tianning Gu, Linqin Wang, et al.. (2022). CAR T-cell therapies in China: rapid evolution and a bright future. The Lancet Haematology. 9(12). e930–e941. 32 indexed citations
10.
Yang, Junfang, Xiao Yan Yang, Ying Liu, et al.. (2021). A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL). Blood. 138(Supplement 1). 652–652. 9 indexed citations
11.
Wu, Xueying, Xian Zhang, Qing Du, et al.. (2021). Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy. Leukemia & lymphoma. 63(2). 426–434. 13 indexed citations
12.
Yang, Junfang, Xian Zhang, Ying Liu, et al.. (2021). High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood. 138(Supplement 1). 473–473. 9 indexed citations
13.
Zhang, Xian, Junfang Yang, Yunchao Su, et al.. (2020). 5 Years of Clinical DC-CIK/NK Cells Immunotherapy for Acute Myeloid Leukemia â€“ a Summary. Immunotherapy. 12(1). 63–74. 8 indexed citations
14.
Zhang, Xian, Jingjing Li, & Peihua Lu. (2020). Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. Chinese Medical Journal. 133(4). 474–482. 6 indexed citations
15.
Ren, Guangxu, et al.. (2019). The Effects of Fecal Donors with Different Feeding Patterns on Diarrhea in a Patient Undergoing Hematopoietic Stem Cell Transplantation. SHILAP Revista de lepidopterología. 2019. 1–11. 5 indexed citations
16.
Zhao, Yu, Zhongfeng Liu, Xuan Wang, et al.. (2019). Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies. Clinical Cancer Research. 25(18). 5595–5607. 34 indexed citations
17.
Yang, Junfang, Pengfei Jiang, Xian Zhang, et al.. (2019). Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 284–284. 21 indexed citations
18.
Zhang, Yang, Fang Wang, Xue Chen, et al.. (2018). CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia. Cancer. 124(16). 3329–3338. 37 indexed citations
19.
Yang, Junfang, Jianqiang Li, Xian Zhang, et al.. (2018). A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 277–277. 19 indexed citations
20.
Pan, Jing, Jieyu Yang, Biping Deng, et al.. (2017). High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 31(12). 2587–2593. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Colette Chaney Breakdown of academic impact, for papers by Haruko Tashiro Breakdown of academic impact, for papers by Yongxian Hu Breakdown of academic impact, for papers by Corinne Summers Breakdown of academic impact, for papers by Colleen Annesley Breakdown of academic impact, for papers by Sarah Tettamanti Breakdown of academic impact, for papers by Rayne H. Rouce Breakdown of academic impact, for papers by Gerrit Weber Breakdown of academic impact, for papers by Maksim Mamonkin Breakdown of academic impact, for papers by Monica Casucci
Rankless by CCL
2026